← Return to Archives - Subscribe to FREE NewsFetch Email Newsletter
From: lewis.perdue@wineindustryinsight.com

Subject: 14 Reasons the new NIH/industry-funded moderate alcohol & health study is on track to be a $100 Million flop - WINE EXECUTIVE NEWS - November 29, 2017

Date: 2017-11-29 09:41:27

To: Emailing List Subscriber
Please use CMD+F (Mac) or CRTL+ F(Windows) to find your specific search term within this issue of NewsFetch. This "double search" is due to our links sourcing from websites not within WineIndustryInsight.
Global tech entrepreneur emerges as white knight to end bitter Sullivan Vineyards bankruptcy| November 29, 2017
You are receiving this email because you are a premium VIP subscriber to Wine Executive News Premium Member.

If you do not wish to receive this, please click the following link: >>>> [UNSUBSCRIBE] <<<<


Screen Shot 2016-11-28 at 1.38.22 PM

VIP Wine Executive News Member Briefing

The premium, VIP service of Wine Industry Insight

From editor & publisher, Lewis Perdue
November 29, 2017


14 Reasons the new NIH/industry-funded moderate alcohol & health study is on track to be a $100 Million flop

The full premium article has been sent to the Principal Investigator of the study for comment. Those will be added when and if received.
  The new $100-million-dollar, government/industry-funded study on moderate alcohol consumption -- first reported by Wine Industry Insight almost three years ago and expanded upon this year by the NY Times -- could set a record as one of the most flawed, least relevant, and least credible studies ever to be supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) -- part of the National Institutes of Health (NIH).

Key Problems

  1. Healthy participants are specifically excluded.
  2. Only people with diagnosed cardiovascular conditions and risks (including previous strokes and heart attacks) are allowed.
  3. No one below the age of 50 is allowed. That minimizes the relevance to most of the population.
  4. Industry funding and previous industry support of study investigators will deal a blow to credibility
  5. The drug treatments for CVD will vary from subject to subject. No way to separate effects of alcohol consumption/abstention from CVD pharmaceuticals and treatment.
  6. Women are mistakenly treated as men for alcohol dosage.
  7. Tobacco smokers are allowed.
  8. Cannabis use is not addressed despite the fact that 24% of the test demographic are users and the health effects of combined alcohol and marijuana use is unknown.
  9. Fails to consider the effects of lifelong moderate consumption.
  10. Vague or no requirements or controls regarding time or circumstances of consumption, diet, or exercise.
  11. Industry funding offers an appearance of conflicts of interest that assures the study will not be accepted as a valid, unbiased study by a large number of the general public, along with physicians, public policy makers a regulators.
  12. No data sharing with outside researchers: thwarts transparency, no reproducibility, damages credibility.
  13. Potential compliance issues with smokers or reformed smokers.
  14. No provision for test subject bias or placebo effect.
  15. The study leaves a huge amount of science undone

The remainder of this major 4,040-word article is available to Wine Executive News premium subscribers who can log-in here:

Also In This Article:

The full text of the following sections is available to premium subscribers of Wine Executive News.

  • People aged 50 years and older with cardiovascular issue only -- Healthy people excluded.

  • Limited relevance: Sick people only

  • Sick people are good from a practical standpoint: They get sicker faster and die quicker (high background rate of events)

  • Study & industry funding first reported by Wine Industry Insight.

  • Industry funding delivers a credibility blow from the beginning.

  • Americans have a dim view of industry-financed studies

  • Drug and treatments regimes for CVD will vary and confound results

  • Fails to consider the effects of lifelong moderate consumption

  • Fails to recognize that men and women are not physiologically identical

  • Tobacco smokers welcome

  • Potential compliance issues with smokers or reformed smokers

  • No consideration of cannabis

  • No provision for bias or placebo effect

  • Moderate consumer subject randomization & compliance issues

  • Failure to share data with other researchers damages credibility

  • Social Interaction Effects

  • Failure to assess/correct effects of BAC and gender

  • No protocol for when or how the "dose" is administered

  • Inadequate control and consideration of diet

  • Inadequate control and consideration of exercise

  • Study protocol wastes golden opportunity, leaves a huge amount of science on the table

Not a Wine Executive News subscriber?

Subscribe to Wine Executive News now, and get the rest of this original article along with everything else on the site every day, including original documents, spreadsheets,and source materials for just $29.99 per month or $209 per year    
New Subscriber Info

For those of you who read our free daily News Fetch email links, some of the following may be redundant.

However -- especially for new subscribers -- it's important to know that I don't send you a separate email every time an article contains premium content. That would be spamming ... especially for folks who read News Fetch every day.

This is because most Wine Executive News subscribers usually have subscribed to News Fetch prior to joining the premium content site.

When you sign up for premium, I always check to see if you are also getting the free News Fetch. If not, I sign you up so you will get the news quickly.

Where can you find premium content?

Every article that contains premium content will usually be the top link in the News Fetch unless some monumental news bumps it to #2.

Screen Shot 2016-11-28 at 4.29.49 PM
For your convenience and future reference, all of the News Fetch emails are automatically converted to web pages and can be found here: NewsFetch Newsletter Archives.

In addition, articles that contain premium content will also be in the "Features" category on the Wine Industry Insight web site:
Screen Shot 2016-11-28 at 4.24.57 PM


================= CONTACT DATA ====================
Lewis Perdue
670 W. Napa St., Suite H, Sonoma, CA 95476
Phone: 707-326-4503, fax: 707-940-4146
Email: lewis.perdue@wineindustryinsight.com